SCHEMBL29348127

SCHEMBL29348127

CN(C)c1nn(CC(=O)Nc2ccc3nncn3n2)c(=O)c2ccc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 3/20 0.46
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
TP53 P04637 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38
AKR1B1 P15121 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
POLB P06746 3/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
S1PR2 O95136 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PSMD14 O00487 1/20 0.35
USP2 O75604 1/20 0.35
PRNP P04156 1/20 0.35
MMP2 P08253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29348128 0.89 NLRP3 (0.46) NLRP3KMT2ATP53RXFP1SMN1; SMN2
SCHEMBL29348126 0.87 NLRP3 (0.44) NLRP3TP53AKR1B1SMN1; SMN2TSHR
SCHEMBL24077182 0.84 NLRP3 (0.47) NLRP3KMT2AMEN1TP53RXFP1
SCHEMBL29348120 0.84 NLRP3 (0.53) NLRP3KMT2AMEN1TP53RXFP1
SCHEMBL29348121 0.82 KMT2A (0.46) KMT2AMEN1TP53RXFP1AKR1B1
SCHEMBL29348125 0.80 NLRP3 (0.53) NLRP3KMT2AMEN1TP53RXFP1
SCHEMBL24834599 0.79 NLRP3 (0.42) NLRP3KMT2AMEN1AKR1B1SMN1; SMN2
SCHEMBL24834601 0.79 NLRP3 (0.41) NLRP3KMT2AMEN1TP53AKR1B1
SCHEMBL29348124 0.79 MEN1 (0.43) KMT2AMEN1TP53RXFP1AKR1B1
SCHEMBL29348083 0.76 S1PR2 (0.46) KMT2AMEN1AKR1B1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239757-A1 PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239757-A1 PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, PYCARD NLRP3 1/4885KMT2A 1964/4885MEN1 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.